

Hongying Gao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/37427/publications.pdf>

Version: 2024-02-01

14
papers

1,185
citations

840776

11
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

1383
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. <i>Nature Chemical Biology</i> , 2021, 17, 567-575.	8.0	76
2	Design, synthesis, and biological evaluation of multiple targeting antimalarials. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2900-2913.	12.0	3
3	Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. <i>Antiviral Research</i> , 2021, 194, 105161.	4.1	6
4	Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1855-1862.	2.8	50
5	Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 8567-8583.	6.4	52
6	PROTAC Technology: Opportunities and Challenges. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 237-240.	2.8	169
7	Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4908-4928.	6.4	38
8	FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice. <i>Protein and Cell</i> , 2020, 11, 534-539.	11.0	24
9	Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degradere. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7575-7582.	6.4	127
10	PROTACs: great opportunities for academia and industry. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 64.	17.1	367
11	Synthesis of Quaternary Carbon-Centered Benzoindolizidinones via Novel Photoredox-Catalyzed Alkene Aminoarylation: Facile Access to Tylophorine and Analogues. <i>CCS Chemistry</i> , 2019, 1, 352-364.	7.8	10
12	Developing Equipotent Teixobactin Analogues against Drug-Resistant Bacteria and Discovering a Hydrophobic Interaction between Lipid II and Teixobactin. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3409-3421.	6.4	35
13	PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. <i>Cell Research</i> , 2018, 28, 779-781.	12.0	215
14	Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4553-4559.	3.0	13